Viewing Study NCT00431795


Ignite Creation Date: 2025-12-24 @ 2:17 PM
Ignite Modification Date: 2026-01-04 @ 12:10 AM
Study NCT ID: NCT00431795
Status: TERMINATED
Last Update Posted: 2013-02-13
First Post: 2007-02-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
Sponsor: Hellenic Oncology Research Group
Organization:

Organization Data

Organization:
Class: OTHER
Study ID: CT/03.12
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type: SPONSOR
Responsible Party Affiliation:
Old Name: None
Old Organization: None

Collaborators

Collaborators

Name Class View
None OTHER View